Photocure ASA (OB: PHO)
Health Care · Pharmaceuticals · NO
Nkr54.00
-0.18% today · -13.0% 1Y
Photocure ASA (OB: PHO) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $156.54M and employs 100 people.
Over the last twelve months the share price has lost 13.0%, trading between 46.25 and 79.80.
Tweenvest scores Photocure ASA across four factors: quality 66/100, value 68/100, growth 50/100. Its strongest factor is value.
PHO price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $156.54M
- Revenue (TTM)
- $68.52M
- P/E
- 18.42
- EPS
- 2.94
- Dividend yield
- —
- Beta (5Y)
- 0.34
- 52-week high
- Nkr79.80
- 52-week low
- Nkr46.25
- Avg volume (3M)
- —
- Shares outstanding
- 26.92M
- Employees
- 100
- Next earnings
- —
About Photocure ASA
Photocure ASA is a specialized pharmaceutical enterprise focused on the development, manufacturing, commercialization, and distribution of medicinal products. Its operational footprint extends across multiple European nations, including the Nordic region, Germany, France, Austria, the United Kingdom, the Netherlands, and Italy, in addition to the United States. The company's primary offering, Hexvix/Cysview, aids in the identification and ongoing management of bladder cancer. Moreover, Photocure is actively progressing Cevira, a therapeutic agent in development targeting human papilloma virus (HPV) infections and pre-cancerous lesions of the cervix. The firm distributes its products to pharmaceutical wholesalers, pharmacies, and healthcare institutions through collaborative licensing arrangements. Founded in 1993, Photocure ASA maintains its corporate headquarters in Oslo, Norway.
- ISIN
- NO0010000045
- Founded
- 1993
- Listed since
- May 30, 2000
- Exchange
- Oslo Bors
- Currency
- NOK
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,246.93 | -0.67% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $273.04 | +1.04% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $150.66 | -1.24% |
| Roche Holding AGSWX: ROP | $373.91B | CHF370.40 | -1.38% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £121.10 | -1.06% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $27.97 | -0.36% |
Figures last refreshed Aug 18, 2026.